Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 30Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 5Breast Neoplasms 3Prostate Carcinoma Metastatic to the Bone 2Neoplasms 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Thyroid Neoplasms 1Prostate Cancer Metastatic to Bone 1Pain 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lung Neoplasms 1Fractures, Bone 1Fatigue 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bony Metastases From Castrate Refractory Prostate Cancer 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

radium Ra 223 dichloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bony Metastases From Castrate Refractory Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT03368989 2019-06-11

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

The University of Texas Health Science Center, Houston

Completed
21 enrolled
Genitourinary

Bony Metastases From Castrate Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡